Managing Partner, Wellington Partners
Regina Hodits
Regina is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of Ayoxxa, Carisma Therapeutics, Endostim, GTX Medical, Themis and TRiCares.
She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / Boston Scientific), and an external director at GlaxoSmithKline's Respiratory TA Board. Since joining the industry in 2000, she has become an influential investor in the European VC industry, focusing on early-stage and growth deals in Life Sciences. She currently serves as the Spokesperson for the Board of the German PE and VC Association (BVK).
Before joining WPLS, Regina led the European life sciences efforts of Boston-based Atlas Venture. She was the founding investor in Bicycle Therapeutics, F-star, and Jenavalve, and served on several Boards, including U3 Pharma (acquired by Daiichi Sankyo), Nitec Pharma (now part of Horizon Pharma NASDAQ HZPN), Egalet (NASDAQ: EGLT), and Novamed (acquired by SciClone NASDAQ SCLN). Before, Regina worked for Apax Partners, and built her extensive network in the global healthcare industry during her tenure at McKinsey. In the 90s, Regina gained initial insights into the fast-growing biotech sector as post-doctoral researcher at the MRC Cambridge UK. Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry.